U.S., Aug. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07124858) titled 'Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer' on Aug. 08.
Brief Summary: The main objective of this study is to identify the prognostic factors (clinico-biological) for the efficacy (overall survival) of fruquintinib in patients with metastatic colorectal cancer.
Study Start Date: March 01, 2026
Study Type: INTERVENTIONAL
Condition:
Metastatic Colorectal Cancer (CRC)
Antineoplastic Agents, Immunological
VEGFR-TKI
Intervention:
DRUG: Fruquintinib
Fruquintinib will be administered according to the summary of product characteristics...